Results · Apr-Jun 2026 · filed 12 Aug 2026
Eiko Lifesciences Q1 FY27 results
Sales grew 56% to ₹16.7 crore from ₹10.7 crore in Apr-Jun 2025.
Operating profit grew 28% to ₹1.9 crore, an operating margin of 11.6% (down 2.5 points from a year ago).
Net profit grew 35% to ₹1.5 crore from ₹1.1 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −9%, net profit +1%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 16.7 | 10.7 | +56% |
| Operating profit (EBITDA) | 1.9 | 1.5 | +28% |
| Operating margin | 11.6% | 14.1% | −2.5 pts |
| Net profit | 1.5 | 1.1 | +35% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 18 Aug 2026Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
- 18 Aug 2026Announcement under Regulation 30 (LODR)-Allotment
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 12 Aug 2026Board Meeting Outcome for Approved Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June, 2026 Along With Limited Review Repo
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.